



Trendlines Exits BioSight Ltd.

MISGAV, Israel, 6 June, 2017 -- The Trendlines Group ("the Group") (SGX: 42T; OTCQX: TRNLY), a leading Israeli investment and innovation commercialization company, focused on early-stage, high growth innovation-based medical and agricultural technologies, today announced the execution of a definitive agreement for the sale of its BioSight Ltd. shares to Arkin Bio Ventures Limited Partnership.

Upon completion of the transaction, the Group is expected to receive net proceeds of approximately US\$1.3 million, pretax (or approximately US\$1.0 million after tax). The completion of the transaction is expected to take place within 14 business days from the signing of the agreement.

BioSight developed a technology and pipeline of cancer drugs that target and release therapeutic drugs inside cancer cells to reduce systemic toxicity associated with conventional chemotherapy treatments. Trendlines' cost basis in BioSight is zero since BioSight was incidentally obtained by the Group as a part of Trendlines Medical-Misgav Ltd. (now named Trendlines Incubators Israel Ltd.) in 2007.

Commenting on the exit from BioSight, Trendlines Chairman and CEO, Steve Rhodes said, "We are pleased to announce this first exit of 2017. Proceeds from the BioSight exit serve to further strengthen our cash position. We look forward to reporting on developments of our other 43 portfolio companies as additional companies move closer to exit."

About Trendlines

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfil its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte.

Ltd. (the "Sponsor"). This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release. This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.

Investor Contact Information:

Israel

Judith Kleinman, Director
Investor Relations & Corporate Communications
The Trendlines Group
judith@trendlines.com
Tel: +972.72.260.7000

Singapore

Reyna MEI
Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

Issuer/Manager THE TRENDLINES GROUP LTD.

Securities THE TRENDLINES GROUP LTD. – IL0011328858 – 42T

Stapled Security No

Announcement Title General Announcement

Date & Time of Broadcast 06 Jun 2017 07:05:55

Status New

Announcement Sub Title Press Release - Trendlines Exits BioSight Ltd.

Announcement Reference SG170606OTHRG8JJ

Submitted By (Co./Ind. Name) Yosef Ron

Designation Joint Company Secretary
